RESUMO
Objectives: Chronic obstructive pulmonary disease (COPD) is a complex inflammatory condition that primarily impairs respiration but can also affect hemostasis. This study aimed to determine differences in platelet-related parameters and eosinophil between COPD patients and healthy controls. Methods: We included 149 patients with stable COPD and 30 healthy controls who were recruited from the outpatient department of Chest Diseases. Complete blood count, including platelet count (Plt), and C-reactive protein were measured. Other platelet-related parameters were determined, including mean platelet volume (MPV), platelet distribution width (PDW), plateletcrit (Pct), their ratios (MPV/Plt, MPV/Pct, PDW/Plt, PDW/Pct), and platelet to lymphocyte ratio (PLR). Results: COPD patients and controls did not show significant differences in platelet parameters (Plt, Pct, PDW, MPV, PDW/Pct, MPV/Pct). PLR was significantly higher in the patient groups than in the control group (p=0.009). Correlation between platelet count and PLR (p=0.047; p=0.05) showed borderline significance. However, we found no correlation between the patients' CRP levels, Pct, PDW, PDW/Pct, MPV/Pct and MPV values. There were no significant differences in platelet parameters in patients using and not using long-acting muscarinic antagonists (LAMA). We did not find differences in eosinophil levels among COPD severity grades. Conclusion: In our study, we found that PLR is elevated in COPD. PLR could be a useful and easily accessible parameter to evaluate ongoing inflammation in stable COPD. Large-scale studies are warranted to further investigate the role of platelet and eosinophil parameters in COPD.
RESUMO
INTRODUCTION: Studies have shown that iron metabolism is affected by coronavirus disease 19 (COVID-19), which has spread worldwide and has become a global health problem. Our study aimed to evaluate the relationship between COVID-19 and serum erythropoietin (EPO), hepcidin, and haptoglobin (Hpt) levels with disease severity, and other biochemical values. METHODS: Fifty nine COVID-19 patients hospitalized in the intensive care unit (ICU) and wards in our hospital between March and June 2020 and 19 healthy volunteers were included in the study. Participants were divided into mild, severe, and critical disease severity groups. Group mean values were analyzed with SPSS according to disease severity, mortality, and intubation status. RESULTS: Hemoglobin (Hb) levels were significantly lower in the critical patient group (P < .0001) and deceased group (P < .0001). The red blood cell distribution width-coefficient of variation (RDW-CV) and ferritin values were significantly higher in the intubated (P = .001, P = .005) and deceased (P = .014, P = .003) groups. Ferritin values were positively correlated with disease severity (P < .0001). Serum iron levels were lower in the patient group compared with the reference range. (P < .0001). It was found that the transferrin saturation (TfSat) was lower in the patient group compared with the control group (P < .0001). It was found that the mean EPO of the deceased was lower than the control group and the survived patient group (P = .035). Hepcidin levels were found to be significantly lower in the patient group (P < .0001). Hpt values were found to be significantly lower in the intubated group (P = .004) and the deceased group (P = .042). CONCLUSION: In our study, while serum iron and hepcidin levels decreased in patients diagnosed with COVID-19, we found that EPO and Hpt levels were significantly lower in critical and deceased patient groups. Our study is the first study examining EPO and Hpt levels in patients diagnosed with COVID-19.